Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Uwe Fuhr

Showing results (11-20 of 136) with videos related to

Pageof 14
Sort By:
Clinical Pharmacology and Therapeutics|August 4, 2004
Time response of cytochrome P450 1A2 activity on cessation of heavy smokingMirko S Faber, Uwe Fuhr
European Journal of Clinical Pharmacology|September 18, 2008
Identification of a novel non-functional CYP2D6 allele, CYP2D6*69, in a Caucasian poor metabolizer individualAndrea Gaedigk, Dorothee Frank, Uwe Fuhr
Nature Reviews. Drug Discovery|August 2, 2005
Pharmacogenetics-based therapeutic recommendations--ready for clinical practice?Julia Kirchheiner, Uwe Fuhr, Jürgen Brockmöller
Clinical Pharmacology and Therapeutics|January 30, 2004
Do data presented at an American Society for Clinical Pharmacology and Therapeutics meeting make it to full publication?Markus Riessland, Dorota Tomalik-Scharte, Uwe Fuhr
Clinical Pharmacology and Therapeutics|December 6, 2018
Response to "Impact of Acute Alcohol Exposure on P-Glycoprotein Function at the Blood-Brain Barrier Assessed Using <sup>11</sup> C-Metoclopramide PET Imaging"Chih-Hsuan Hsin, Uwe Fuhr, Christina Trueck
Basic & Clinical Pharmacology & Toxicology|September 1, 2005
Assessment of CYP1A2 activity in clinical practice: why, how, and when?Mirko S Faber, Alexander Jetter, Uwe Fuhr
The AAPS Journal|February 14, 2013
Modeling NSCLC progression: recent advances and opportunities availableAhmed Abbas Suleiman, Lucia Nogova, Uwe Fuhr
Clinical Pharmacokinetics|May 25, 2006
How may anticancer chemotherapy with fluorouracil be individualised?Su-arpa Ploylearmsaeng, Uwe Fuhr, Alexander Jetter
Naunyn-Schmiedeberg'S Archives of Pharmacology|September 19, 2022
A population pharmacokinetic model of remdesivir and its major metabolites based on published mean values from healthy subjectsAhmed Abouellil, Muhammad Bilal, Max Taubert, et al.
European Journal of Clinical Pharmacology|June 20, 2020
The parent drugs chloroquine and hydroxychloroquine do not inhibit human CYP3A activity in vitroXia Li, Rainer Höhl, Fritz Sörgel, et al.
Pageof 14

Showing results (11-20 of 136) with videos related to

Sort By:
Pageof 14
Clinical Pharmacology and Therapeutics|August 4, 2004
Time response of cytochrome P450 1A2 activity on cessation of heavy smokingMirko S Faber, Uwe Fuhr
European Journal of Clinical Pharmacology|September 18, 2008
Identification of a novel non-functional CYP2D6 allele, CYP2D6*69, in a Caucasian poor metabolizer individualAndrea Gaedigk, Dorothee Frank, Uwe Fuhr
Nature Reviews. Drug Discovery|August 2, 2005
Pharmacogenetics-based therapeutic recommendations--ready for clinical practice?Julia Kirchheiner, Uwe Fuhr, Jürgen Brockmöller
Clinical Pharmacology and Therapeutics|January 30, 2004
Do data presented at an American Society for Clinical Pharmacology and Therapeutics meeting make it to full publication?Markus Riessland, Dorota Tomalik-Scharte, Uwe Fuhr
Clinical Pharmacology and Therapeutics|December 6, 2018
Response to "Impact of Acute Alcohol Exposure on P-Glycoprotein Function at the Blood-Brain Barrier Assessed Using <sup>11</sup> C-Metoclopramide PET Imaging"Chih-Hsuan Hsin, Uwe Fuhr, Christina Trueck
Basic & Clinical Pharmacology & Toxicology|September 1, 2005
Assessment of CYP1A2 activity in clinical practice: why, how, and when?Mirko S Faber, Alexander Jetter, Uwe Fuhr
The AAPS Journal|February 14, 2013
Modeling NSCLC progression: recent advances and opportunities availableAhmed Abbas Suleiman, Lucia Nogova, Uwe Fuhr
Clinical Pharmacokinetics|May 25, 2006
How may anticancer chemotherapy with fluorouracil be individualised?Su-arpa Ploylearmsaeng, Uwe Fuhr, Alexander Jetter
Naunyn-Schmiedeberg'S Archives of Pharmacology|September 19, 2022
A population pharmacokinetic model of remdesivir and its major metabolites based on published mean values from healthy subjectsAhmed Abouellil, Muhammad Bilal, Max Taubert, et al.
European Journal of Clinical Pharmacology|June 20, 2020
The parent drugs chloroquine and hydroxychloroquine do not inhibit human CYP3A activity in vitroXia Li, Rainer Höhl, Fritz Sörgel, et al.
Pageof 14